Cancer Clinical Trial Eligibility Criteria: Performance Status: Guidance for Industry, IRBs, and Clinical Investigators
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 27, 2026
July 27, 2026
dd52a281-35b8-4026-8bcb-85671a4ed273
Related Documents
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications: Guidance for Industry, IRBs, and Clinical Investigators
Guidance DocumentJuly 27, 2026Office of the Commissioner
Cancer Clinical Trial Eligibility Criteria: Laboratory Values: Guidance for Industry, IRBs, and Clinical Investigators
Guidance DocumentJuly 27, 2026Office of the Commissioner
Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings: Guidance for Industry
Guidance DocumentJuly 27, 2022Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.